Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain

Free Radical Biology and Medicine

Volumn 62, Issue , 2013, Pages 157-169

  Sultana, Rukhsana ^a   Perluigi, Marzia ^b   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

4 Hydroxy 2 nonenal; ATP synthase; Collapsin regulatory protein 2; Enolase; Lipid peroxidation; Oxidative stress; Proteomics

Indexed keywords

4 HYDROXYNONENAL; ACONITATE HYDRATASE; ACROLEIN; ALCOHOL DEHYDROGENASE; ALDEHYDE; ALDEHYDE REDUCTASE; ALPHA ENOLASE; AMYLOID BETA PROTEIN; BETA ACTIN; CARBONYL DERIVATIVE; CARBONYL REDUCTASE; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; ELONGATION FACTOR TU; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUTATHIONE; HEAT SHOCK PROTEIN 70; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; MALATE DEHYDROGENASE; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN 6; PHOSPHOGLYCERATE KINASE; PLASMINOGEN; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE KINASE; SEMAPHORIN; TRIOSEPHOSPHATE ISOMERASE;

ACETYLATION; ALZHEIMER DISEASE; CHEMICAL BOND; DISEASE ASSOCIATION; GLUCOSE METABOLISM; GLUTATHIONYLATION; HYDROPHOBICITY; LIPID PEROXIDATION; METABOLISM; METHYLATION; MOLECULAR INTERACTION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REDUCTION; REVIEW; SENILE PLAQUE;

EID: 84884877254     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2012.09.027     Document Type: Review

References (170)

1. Esterbauer, H.; Schaur, R. J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11: 81-128; 1991. (Pubitemid 121003917)
2. Pryor, W. A.; Porter, N. A. Suggested mechanisms for the production of 4-hydroxy-2-nonenal from the autoxidation of polyunsaturated fatty acids. Free Radic. Biol. Med 8: 541-543; 1990. (Pubitemid 20204418)
3. Loidl-Stahlhofen, A.; Hannemann, K.; Spiteller, G. Generation of alpha-hydroxyaldehydic compounds in the course of lipid peroxidation. Biochim. Biophys. Acta 1213: 140-148; 1994.
4. Morrow, J. D.; Awad, J. A.; Kato, T.; Takahashi, K.; Badr, K. F.; Roberts 2nd L. J.; Burk, R. F. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. An animal model of lipid peroxidation. J. Clin. Invest. 90: 2502-2507; 1992. (Pubitemid 23010071)
5. Musiek, E. S.; Yin, H.; Milne, G. L.; Morrow, J. D. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 40: 987-994; 2005.
6. Roberts 2nd L. J.; Montine, T. J.; Markesbery, W. R.; Tapper, A. R.; Hardy, P.; Chemtob, S.; Dettbarn, W. D.; Morrow, J. D. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273: 13605-13612; 1998. (Pubitemid 28268404)
7. Montuschi, P.; Barnes, P.; Roberts 2nd L. J. Insights into oxidative stress: the isoprostanes. Curr. Med. Chem. 14: 703-717; 2007. (Pubitemid 46477722)
8. Roberts 2nd L. J.; Fessel, J. P.; Davies, S. S. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol. 15: 143-148; 2005. (Pubitemid 40546170)
9. Radak, Z.; Zhao, Z.; Goto, S.; Koltai, E. Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA. Mol. Aspects Med. 32: 305-315; 2011.
10. Anzai, K.; Ogawa, K.; Goto, Y.; Senzaki, Y.; Ozawa, T.; Yamamoto, H. Oxidation-dependent changes in the stability and permeability of lipid bilayers. Antioxid. Redox Signal. 1: 339-347; 1999. (Pubitemid 129622804)
11. Yehuda, S.; Rabinovitz, S.; Carasso, R. L.; Mostofsky, D. I. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol. Aging 23: 843-853; 2002. (Pubitemid 35217710)
12. Farooqui, A. A.; Horrocks, L. A. Lipid peroxides in the free radical patho-physiology of brain diseases. Cell. Mol. Neurobiol. 18: 599-608; 1998. (Pubitemid 29012939)
13. Moreira, P. I.; Santos, M. S.; Oliveira, C. R.; Shenk, J. C.; Nunomura, A.; Smith, M. A.; Zhu, X.; Perry, G. Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol. Disord. Drug Targets 7: 3-10; 2008. (Pubitemid 351516211)
14. Lovell, M. A.; Markesbery, W. R. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35: 7497-7504; 2007.
15. Sultana Butterfield, R. D.A. Role of oxidative stress in the progression of Alzheimer's disease. J. Alzheimers Dis 19: 341-353; 2010.
16. Martinez, A.; Portero-Otin, M.; Pamplona, R.; Ferrer, I. Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol 20: 281-297; 2010.
17. Butterfield, D. A.; Bader Lange, M. L.; Sultana, R. Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease. Biochim. Biophys. Acta 1801: 924-929; 2010.
18. Lee, J.; Kosaras, B.; Del Signore, S. J.; Cormier, K.; McKee, A.; Ratan, R. R.; Kowall, N. W.; Ryu, H. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathol. 121: 487-498; 2011.
19. Ruiperez, V.; Darios, F.; Davletov, B. Alpha-synuclein, lipids and Parkinson's disease. Prog. Lipid Res. 49: 420-428; 2010.
20. Sajdel-Sulkowska, E. M.; Marotta, C. A. Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. Science 225: 947-949; 1984. (Pubitemid 14064179)
21. Shichiri, M.; Yoshida, Y.; Ishida, N.; Hagihara, Y.; Iwahashi, H.; Tamai, H.; Niki, E. Alpha-tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Free Radic. Biol. Med. 50: 1801-1811; 2011.
22. Subbarao, K. V.; Richardson, J. S.; Ang, L. C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55: 342-345; 1990.
23. Ferrante, R. J.; Browne, S. E.; Shinobu, L. A.; Bowling, A. C.; Baik, M. J.; MacGarvey, U.; Kowall, N. W.; Brown Jr. R. H.; Beal, M. F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69: 2064-2074; 1997. (Pubitemid 27452754)
24. Esterbauer, H.; Cheeseman, K. H. Determination of aldehydic lipid perox-idation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 186: 407-421; 1990. (Pubitemid 20279982)
25. Behl, C. Vitamin E and other antioxidants in neuroprotection. Int. J. Vitam. Nutr. Res. 69: 213-219; 1999. (Pubitemid 29266983)
26. Dhitavat, S.; Rivera, E. R.; Rogers, E.; Shea, T. B. Differential efficacy of lipophilic and cytosolic antioxidants on generation of reactive oxygen species by amyloid-beta. J. Alzheimers Dis 3: 525-529; 2001. (Pubitemid 34003204)
27. Siow, R. C.; Ishii, T.; Mann, G. E. Modulation of antioxidant gene expression by 4-hydroxynonenal: atheroprotective role of the Nrf2/ARE transcription pathway. Redox Rep 12: 11-15; 2007. (Pubitemid 46210347)
28. Vander Jagt, D. L.; Hunsaker, L. A.; Vander Jagt, T. J.; Gomez, M. S.; Gonzales, D. M.; Deck, L. M.; Royer, R. E. Inactivation of glutathione reductase by 4-hydroxynonenal and other endogenous aldehydes. Biochem. Pharmacol. 53: 1133-1140; 1997. (Pubitemid 27224259)
29. Pratt, D. A.; Tallman, K. A.; Porter, N. A. Free radical oxidation of poly-unsaturated lipids: new mechanistic insights and the development of peroxyl radical clocks. Acc. Chem. Res. 44: 458-467; 2011.
30. Esterbauer, H.; Benedetti, A.; Lang, J.; Fulceri, R.; Fauler, G.; Comporti, M. Studies on the mechanism of formation of 4-hydroxynonenal during microsomal lipid peroxidation. Biochim. Biophys. Acta 876: 154-166; 1986. (Pubitemid 16011009)
31. Schneider, C.; Porter, N. A.; Brash, A. R. Autoxidative transformation of chiral omega6 hydroxy linoleic and arachidonic acids to chiral 4-hydroxy-2E-nonenal. Chem. Res. Toxicol 17: 937-941; 2004. (Pubitemid 38955353)
32. Perluigi, M.; Coccia, R.; Butterfield, D. A. 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies; 2012Antioxid. Redox Signal; 2012.
33. Uchida, K.; Stadtman, E. R. Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem 268: 6388-6393; 1993. (Pubitemid 23099334)
34. Subramaniam, R.; Roediger, F.; Jordan, B.; Mattson, M. P.; Keller, J. N.; Waeg, G.; Butterfield, D. A. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69: 1161-1169; 1997. (Pubitemid 27364837)
35. Yang, Y.; Sharma, R.; Sharma, A.; Awasthi, S.; Awasthi, Y. C. Lipid peroxida-tion and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim. Pol. 50: 319-336; 2003. (Pubitemid 37034689)
36. Mattson, M. P. Roles of the lipid peroxidation product 4-hydroxynonenal in obesity, the metabolic syndrome, and associated vascular and neurodegen-erative disorders. Exp. Gerontol 44: 625-633; 2009.
37. Pedersen, W. A.; Cashman, N. R.; Mattson, M. P. The lipid peroxidation product 4-hydroxynonenal impairs glutamate and glucose transport and choline acetyltransferase activity in NSC-19 motor neuron cells. Exp. Neurol 155: 1-10; 1999. (Pubitemid 29072599)
38. Butterfield, D. A.; Stadtman, E. R. Protein oxidation processes in aging brain. Advantage Cell Aging Gerontol 2: 161-191; 1997.
39. Poli, G.; Schaur, R. J. 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life 50: 315-321; 2000. (Pubitemid 32289090)
40. Poli, G.; Biasi, F.; Leonarduzzi, G. 4-Hydroxynonenal-protein adducts: a reliable biomarker of lipid oxidation in liver diseases. Mol. Aspects Med. 29: 67-71; 2008.
41. Kehrer, J. P.; Biswal, S. S. The molecular effects of acrolein. Toxicol. Sci. 57: 6-15; 2000.
42. LoPachin, R. M.; Barber, D. S. Synaptic cysteine sulfhydryl groups as targets of electrophilic neurotoxicants. Toxicol. Sci. 94: 240-255; 2006. (Pubitemid 44817140)
43. Doorn, J. A.; Petersen, D. R. Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal. Chem. Biol. Interact. 143-144: 93-100; 2003. (Pubitemid 36246435)
44. Petersen, D. R.; Doorn, J. A. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic. Biol. Med. 37: 937-945; 2004. (Pubitemid 39164576)
45. Siegel, S. J.; Bieschke, J.; Powers, E. T.; Kelly, J. W. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46: 1503-1510; 2007.
46. Owen, J. B.; Sultana, R.; Aluise, C. D.; Erickson, M. A.; Price, T. O.; Bu, G.; Banks, W. A.; Butterfield, D. A. Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD brain. Free Radic. Biol. Med. 49: 1798-1803; 2010.
47. Sultana, R.; Butterfield, D. A. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem. Res 29: 2215-2220; 2004. (Pubitemid 40036893)
48. Guiotto, A.; Calderan, A.; Ruzza, P.; Borin, G. Carnosine and carnosine-related antioxidants: a review. Curr. Med. Chem. 12: 2293-2315; 2005. (Pubitemid 41300782)
49. Mitchell, D. Y.; Petersen, D. R. The oxidation of alpha-beta unsaturated aldehydic products of lipid peroxidation by rat liver aldehyde dehydro-genases. Toxicol. Appl. Pharmacol 87: 403-410; 1987. (Pubitemid 17051163)
50. Picklo, M. J.; Olson, S. J.; Markesbery, W. R.; Montine, T. J. Expression and activities of aldo-keto oxidoreductases in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60: 686-695; 2001. (Pubitemid 32619791)
51. Ohta, S.; Ohsawa, I. Dysfunction of mitochondria and oxidative stress in the pathogenesis of Alzheimer's disease: on defects in the cytochrome c oxidase complex and aldehyde detoxification. J. Alzheimers Dis 9: 155-166; 2006. (Pubitemid 44078643)
52. O'Connor, T.; Ireland, L. S.; Harrison, D. J.; Hayes, J. D. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members. Biochem. J 343(Pt 2): 487-504; 1999. (Pubitemid 29511786)
53. Doorn, J. A.; Maser, E.; Blum, A.; Claffey, D. J.; Petersen, D. R. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry 43: 13106-13114; 2004. (Pubitemid 39366059)
54. Reed, T.; Perluigi, M.; Sultana, R.; Pierce, W. M.; Klein, J. B.; Turner, D. M.; Coccia, R.; Markesbery, W. R.; Butterfield, D. A. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30: 107-120; 2008.
55. Aldini, G.; Vistoli, G.; Regazzoni, L.; Gamberoni, L.; Facino, R. M.; Yamaguchi, S.; Uchida, K.; Carini, M. Albumin is the main nucleophilic target of human plasma: a protective role against pro-atherogenic electrophilic reactive carbonyl species? Chem. Res. Toxicol. 21: 824-835; 2008. (Pubitemid 351644560)
56. Sultana, R.; Perluigi, M.; Butterfield, D. A. Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol 118: 131-150; 2009.
57. Castegna, A.; Aksenov, M.; Aksenova, M.; Thongboonkerd, V.; Klein, J. B.; Pierce, W. M.; Booze, R.; Markesbery, W. R.; Butterfield, D. A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33: 562-571; 2002. (Pubitemid 34874977)
58. Dalle Donne, I.; Scaloni, A.; Butterfield, D. A. Redox Proteomics: from protein modifications to cellular dysfunction and diseases. Hoboken, NJ: Wiley; 2006.
59. Butterfield, D.A.; Perluigi, M.; Reed, T.; Muharib, T.; Hughes, C.P.; Robinson, R.A., Sultana, R. Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid. Redox Signal. 17: 1610-1655; 2012.
60. Perluigi, M.; Butterfield, D. A. The identification of protein biomarkers for oxidative stress in Down syndrome. Expert Rev. Proteomics 8: 427-429; 2011.
61. Scheff, S. W.; Price, D. A.; Schmitt, F. A.; Scheff, M. A.; Mufson, E. J. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 24: 547-557; 2011.
62. Masliah, E.; Mallory, M.; Hansen, L.; DeTeresa, R.; Alford, M.; Terry, R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 174: 67-72; 1994. (Pubitemid 24205235)
63. Duyckaerts, C; Delatour, B.; Potier, M. C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118: 5-36; 2009.
64. Grundke-Iqbal, I.; Iqbal, K.; Quinlan, M.; Tung, Y. C; Zaidi, M. S.; Wis-niewski, H. M. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261: 6084-6089; 1986. (Pubitemid 17207447)
65. West, M. J.; Kawas, C. H.; Stewart, W. F.; Rudow, G. L.; Troncoso, J. C. Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol. Aging 25: 1205-1212; 2004. (Pubitemid 39094023)
66. Morris, J. C; Roe, C. M.; Grant, E. A.; Head, D.; Storandt, M.; Goate, A. M.; Fagan, A. M.; Holtzman, D. M.; Mintun, M. A. PIB imaging predicts progression from cognitive normal to symptomatic Alzheimer's disease. Arch. Neurol. 66: 1469-1475; 2009.
67. Aluise, C. D.; Robinson, R. A.; Beckett, T. L.; Murphy, M. P.; Cai, J.; Pierce, W. M.; Markesbery, W. R.; Butterfield, D. A. Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol. Dis. 39: 221-228; 2010.
68. Aluise, C. D.; Robinson, R. A.; Cai, J.; Pierce, W. M.; Markesbery, W. R.; Butterfield, D. A. Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J. Alzheimers Dis 23: 257-269; 2011.
69. Economou, A.; Papageorgiou, S. G.; Karageorgiou, C; Vassilopoulos, D. Nonepisodic memory deficits in amnestic MCI. Cogn. Behav. Neurol. 20: 99-106; 2007. (Pubitemid 46905205)
70. Petersen, R. C. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15: 93-101; 2000. (Pubitemid 30340226)
71. Devanand, D. P.; Pradhaban, G.; Liu, X.; Khandji, A.; De Santi, S.; Segal, S.; Rusinek, H.; Pelton, G. H.; Honig, L. S.; Mayeux, R.; Stern, Y.; Tabert, M. H.; de Leon, M. J. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 68: 828-836; 2007. (Pubitemid 46568534)
72. Du, A. T.; Schuff, N.; Amend, D.; Laakso, M. P.; Hsu, Y. Y.; Jagust, W. J.; Yaffe, K.; Kramer, J. H.; Reed, B.; Norman, D.; Chui, H. C; Weiner, M. W. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 71: 441-447; 2001. (Pubitemid 32906865)
73. Rozzini, L; Chilovi, B. V.; Conti, M.; Bertoletti, E.; Delrio, I.; Trabucchi, M.; Padovani, A. Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type is independent to memory deterioration. Int. J. Geriatr. Psychiatry 22: 1217-1222; 2007. (Pubitemid 350285426)
74. Sultana, R.; Boyd-Kimball, D.; Poon, H. F.; Cai, J.; Pierce, W. M.; Klein, J. B.; Merchant, M.; Markesbery, W. R.; Butterfield, D. A. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging 27: 1564-1576; 2006. (Pubitemid 44344840)
75. Scheff, S. W.; DeKosky, S. T.; Price, D. A. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol. Aging 11: 29-37; 1990. (Pubitemid 20097857)
76. Ansari, M. A.; Scheff, S. W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J. Neuropathol. Exp. Neurol. 69: 155-167; 2010.
77. Butterfield, D. A.; Drake, J.; Pocernich, C; Castegna, A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7: 548-554; 2001. (Pubitemid 33127140)
78. Markesbery, W. R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23: 134-147; 1997. (Pubitemid 27217017)
79. Smith, C. D.; Carney, J. M.; Starkereed, P. E.; Oliver, C. N.; Stadtman, E. R.; Floyd, R. A.; Markesbery, W. R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer-disease. Proc. Natl. Acad. Sci. USA 88: 10540-10543; 1991. (Pubitemid 21915871)
80. Smith, M. A.; Sayre, L. M.; Anderson, V. E.; Harris, P. L.; Beal, M. F.; Kowall, N.; Perry, G. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J. Histochem. Cytochem. 46: 731-735; 1998. (Pubitemid 28272207)
81. Lauderback, C. M.; Hackett, J. M.; Huang, F. F.; Keller, J. N.; Szweda, L. I.; Markesbery, W. R.; Butterfield, D. A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J. Neurochem. 78: 413-416; 2001. (Pubitemid 32664423)
82. Markesbery, W. R.; Kryscio, R. J.; Lovell, M. A.; Morrow, J. D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 58: 730-735; 2005. (Pubitemid 41552548)
83. Yao, Y.; Zhukareva, V.; Sung, S.; Clark, C. M.; Rokach, J.; Lee, V. M.; Trojanowski, J. Q.; Pratico, D. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology 61: 475-478; 2003. (Pubitemid 37025363)
84. Keller, J. N.; Schmitt, F. A.; Scheff, S. W.; Ding, Q.; Chen, Q.; Butterfield, D. A.; Markesbery, W. R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156; 2005.
85. Butterfield, D. A.; Reed, T.; Perluigi, M.; De Marco, C; Coccia, R.; Cini, C; Sultana, R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 397: 170-173; 2006.
86. Pratico, D.; Sung, S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J. Alzheimers Dis 6: 171-175; 2004. (Pubitemid 38560253)
87. Pratico, D.; Clark, C. M.; Liun, F.; Rokach, J.; Lee, V. Y.; Trojanowski, J. Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59: 972-976; 2002. (Pubitemid 34640757)
88. Pamplona, R.; Dalfo, E.; Ayala, V.; Bellmunt, M. J.; Prat, J.; Ferrer, I.; Portero-Otin, M. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. 280: 21522-21530; 2005. (Pubitemid 40805718)
89. Liu, X.; Lovell, M. A.; Lynn, B. C. Development of a method for quantification of acrolein-deoxyguanosine adducts in DNA using isotope dilution-capillary LC/MS/MS and its application to human brain tissue. Anal. Chem 77: 5982-5989; 2005. (Pubitemid 41324300)
90. Quinn, J. F.; Montine, K. S.; Moore, M.; Morrow, J. D.; Kaye, J. A.; Montine, T. J. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J. Alzheimers Dis. 6: 93-97; 2004. (Pubitemid 38418561)
91. Castegna, A.; Aksenov, M.; Thongboonkerd, V.; Klein, J. B.; Pierce, W. M.; Booze, R.; Markesbery, W. R.; Butterfield, D. A. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J. Neurochem. 82: 1524-1532; 2002.
92. Butterfield, D. A.; Gnjec, A.; Poon, H. F.; Castegna, A.; Pierce, W. M.; Klein, J. B.; Martins, R. N. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 10: 391-397; 2006.
93. Castegna, A.; Thongboonkerd, V.; Klein, J. B.; Lynn, B.; Markesbery, W. R.; Butterfield, D. A. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85: 1394-1401; 2003. (Pubitemid 36702552)
94. Sultana, R.; Poon, H. F.; Cai, J.; Pierce, W. M.; Merchant, M.; Klein, J. B.; Markesbery, W. R.; Butterfield, D. A. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22: 76-87; 2006.
95. Reed, T. T.; Pierce Jr W. M.; Turner, D. M.; Markesbery, W. R.; Butterfield, D. A. Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J. Cell. Mol. Med. 13: 2019-2029; 2009.
96. Perluigi, M.; Sultana, R.; Cenini, G.; Di Domenico, F.; Memo, M.; Pierce, W. M.; Coccia, R.; Butterfield, D. A. Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin. Appl. 3: 682-693; 2009.
97. Newman, S. F.; Sultana, R.; Perluigi, M.; Coccia, R.; Cai, J.; Pierce, W. M.; Klein, J. B.; Turner, D. M.; Butterfield, D. A. An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J. Neurosci. Res. 85: 1506-1514; 2007. (Pubitemid 46724394)
98. Petrak, J.; Ivanek, R.; Toman, O.; Cmejla, R.; Cmejlova, J.; Vyoral, D.; Zivny, J.; Vulpe, C. D. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 8: 1744-1749; 2008. (Pubitemid 351678270)
99. Mielke, R.; Schroder, R.; Fink, G. R.; Kessler, J.; Herholz, K.; Heiss, W. D. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. 91: 174-179; 1996. (Pubitemid 26021405)
100. de Leon, M. J.; Convit, A.; Wolf, O. T.; Tarshish, C. Y.; DeSanti, S.; Rusinek, H.; Tsui, W.; Kandil, E.; Scherer, A. J.; Roche, A.; Imossi, A.; Thorn, E.; Bobinski, M.; Caraos, C.; Lesbre, P.; Schlyer, D.; Poirier, J.; Reisberg, B.; Fowler, J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. USA 98: 10966-10971; 2001. (Pubitemid 32878727)
101. Sultana Boyd-Kimball, R.; Cai, D.; Pierce, J.; Klein, W. M.; Merchant, J. B.; Butterfield, M. D.A. Proteomics analysis of the Alzheimer's disease hippo-campal proteome. J. Alzheimers Dis. 11: 153-164; 2007.
102. Butterfield, D. A.; Lange, M. L. Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J. Neurochem. 111: 915-933; 2009.
103. Pancholi, V. Multifunctional alpha-enolase: its role in diseases. Cell. Mol. Life Sci. 58: 902-920; 2001. (Pubitemid 32652817)
104. Hattori, T.; Takei, N.; Mizuno, Y.; Kato, K.; Kohsaka, S. Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci. Res. 21: 191-198; 1995.
105. Takei, N.; Kondo, J.; Nagaike, K.; Ohsawa, K.; Kato, K.; Kohsaka, S. Neuronal survival factor from bovine brain is identical to neuron-specific enolase. J. Neurochem. 57: 1178-1184; 1991. (Pubitemid 21922739)
106. Aaronson, R. M.; Graven, K. K.; Tucci, M.; McDonald, R. J.; Farber, H. W. Non-neuronal enolase is an endothelial hypoxic stress protein. J. Biol. Chem. 270: 27752-27757; 1995.
107. Ray, R.; Miller, D. M. Cloning and characterization of a human c-myc promoter-binding protein. Mol. Cell. Biol. 11: 2154-2161; 1991. (Pubitemid 21895587)
108. Nakajima, K.; Hamanoue, M.; Takemoto, N.; Hattori, T.; Kato, K.; Kohsaka, S. Plasminogen binds specifically to alpha-enolase on rat neuronal plasma membrane. J. Neurochem. 63: 2048-2057; 1994. (Pubitemid 24369977)
109. Pancholi, V.; Fischetti, V. A. alpha-enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J. Biol. Chem 273: 14503-14515; 1998. (Pubitemid 28319172)
110. Plow, E. F.; Felez, J.; Miles, L. A. Cellular regulation of fibrinolysis. Thromb. Haemost. 66: 32-36; 1991.
111. Bergman, A. C.; Linder, C.; Sakaguchi, K.; Sten-Linder, M.; Alaiya, A. A.; Franzen, B.; Shoshan, M. C.; Bergman, T.; Wiman, B.; Auer, G.; Appella, E.; Jornvall, H.; Linder, S. Increased expression of alpha-enolase in c-jun transformed rat fibroblasts without increased activation of plasminogen. FEBS Lett 417: 17-20; 1997. (Pubitemid 27490464)
112. Carmeliet, P.; Schoonjans, L.; Kieckens, L.; Ream, B.; Degen, J.; Bronson, R.; De Vos, R.; van den Oord, J. J.; Collen, D.; Mulligan, R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424; 1994. (Pubitemid 24115347)
113. Redlitz, A.; Fowler, B. J.; Plow, E. F.; Miles, L. A. The role of an enolase-related molecule in plasminogen binding to cells. Eur. J. Biochem. 227: 407-415; 1995.
114. Kranenburg, O.; Bouma, B.; Kroon-Batenburg, L. M.; Reijerkerk, A.; Wu, Y. P.; Voest, E. E.; Gebbink, M. F. Tissue-type plasminogen activator is a multi-ligand cross-beta structure receptor. Curr. Biol. 12: 1833-1839; 2002. (Pubitemid 35273903)
115. Kingston, I. B.; Castro, M. J.; Anderson, S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues. Nat. Med 1: 138-142; 1995.
116. Van Nostrand, W. E.; Porter, M. Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasmi-nogen activator activity. Biochemistry 38: 11570-11576; 1999.
117. Cornelius, Calabrese, V.; Mancuso, C.; Barone, C.; Calafato, E.; Bates, S.; Rizzarelli, T.; Kostova, E.; Vitagenes, A. T. dietary antioxidants and neuro-protection in neurodegenerative diseases. Front. Biosci. 14: 376-397; 2009.
118. Poon, H. F.; Calabrese, V.; Scapagnini, G.; Butterfield, D. A. Free radicals: key to brain aging and heme oxygenase as a cellular response to oxidative stress. J. Gerontol. A Biol. Sci. Med. Sci 59: 478-493; 2004. (Pubitemid 38649940)
119. Maines, M. D. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37: 517-554; 1997. (Pubitemid 27238886)
120. Mancuso, C. Heme oxygenase and its products in the nervous system. Antioxid. Redox Signal 6: 878-887; 2004. (Pubitemid 39237941)
121. Mancuso, C.; Barone, E. The heme oxygenase/biliverdin reductase pathway in drug research and development. Curr. Drug Metab 10: 579-594; 2009.
122. Kapitulnik, J.; Maines, M. D. Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin. Trends Pharmacol. Sci 30: 129-137; 2009.
123. Dwyer, B. E.; Nishimura, R. N.; Lu, S. Y. Differential expression of heme oxygenase-1 in cultured cortical neurons and astrocytes determined by the aid of a new heme oxygenase antibody. Response to oxidative stress. Brain Res. Mol. Brain Res 30: 37-47; 1995.
124. Calabrese Scapagnini, V.; Colombrita, G.; Ravagna, C.; Pennisi, A.; Giuffrida Stella, G.; Galli, A. M.; Butterfield, F. D.A. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25: 437-444; 2003.
125. Takeda, A.; Perry, G.; Abraham, N. G.; Dwyer, B. E.; Kutty, R. K.; Laitinen, J. T.; Petersen, R. B.; Smith, M. A. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J. Biol. Chem. 275: 5395-5399; 2000. (Pubitemid 30115170)
126. Hui, Y.; Wang, D.; Li, W.; Zhang, L.; Jin, J.; Ma, N.; Zhou, L.; Nakajima, O.; Zhao, W.; Gao, X. Long-term overexpression of heme oxygenase 1 promotes tau aggregation in mouse brain by inducing tau phosphorylation. J. Alzheimers Dis. 26: 299-313; 2011.
127. Schipper, H. M.; Gupta, A.; Szarek, W. A. Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Curr. Alzheimer Res. 6: 424-430; 2009.
128. Premkumar, D. R.; Smith, M. A.; Richey, P. L.; Petersen, R. B.; Castellani, R.; Kutty, R. K.; Wiggert, B.; Perry, G.; Kalaria, R. N. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J. Neurochem. 65: 1399-1402; 1995.
129. Barone, E.; Di Domenico, F.; Sultana, R.; Coccia, R.; Mancuso, C.; Perluigi, M.; Butterfield, D. A. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic. Biol. Med. 52: 2292-2301; 2012.
130. Salinas, M.; Wang, J.; Rosa de Sagarra, M.; Martin, D.; Rojo, A. I.; Martin-Perez, J.; Ortiz de Montellano, P. R.; Cuadrado, A. Protein kinase Akt/PKB phosphorylates heme oxygenase-1 in vitro and in vivo. FEBS Lett 578: 90-94; 2004. (Pubitemid 39576106)
131. Di Domenico, F.; Sultana, R.; Tiu, G. F.; Scheff, N. N.; Perluigi, M.; Cini, C.; Butterfield, D. A. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res 1333: 72-81; 2010.
132. Rahajeng, J.; Giridharan, S. S.; Naslavsky, N.; Caplan, S. Collapsin response mediator protein-2 (Crmp2) regulates trafficking by linking endocytic regulatory proteins to dynein motors. J. Biol. Chem. 285: 31918-31922; 2010.
133. Quach, T. T.; Duchemin, A. M.; Rogemond, V.; Aguera, M.; Honnorat, J.; Belin, M. F.; Kolattukudy, P. E. Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons. Mol. Cell. Neurosci. 25: 433-443; 2004. (Pubitemid 38366408)
134. Hensley, K.; Christov, A.; Kamat, S.; Zhang, X. C.; Jackson, K. W.; Snow, S.; Post, J. Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures. J. Neurosci. 30: 2979-2988; 2010.
135. Shankar, G. M.; Walsh, D. M. Alzheimer's disease: synaptic dysfunction and Abeta. Mol. Neurodegener 4: 48; 2009.
136. Cole, A. R.; Causeret, F.; Yadirgi, G.; Hastie, C. J.; McLauchlan, H.; McManus, E. J.; Hernandez, F.; Eickholt, B. J.; Nikolic, M.; Sutherland, C. Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J. Biol. Chem. 281: 16591-16598; 2006.
137. Schmidt, E. F.; Strittmatter, S. M. The CRMP family of proteins and their role in Sema3A signaling. Adv. Exp. Med. Biol. 600: 1-11; 2007.
138. Hou, S. T.; Jiang, S. X.; Aylsworth, A.; Ferguson, G.; Slinn, J.; Hu, H.; Leung, T.; Kappler, J.; Kaibuchi, K. CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J. Neurochem. 111: 870-881; 2009.
139. Uchida, Y.; Ohshima, T.; Yamashita, N.; Ogawara, M.; Sasaki, Y.; Nakamura, F.; Goshima, Y. Semaphorin3A signaling mediated by Fyn-dependent tyrosine phosphorylation of collapsin response mediator protein 2 at tyrosine 32. J. Biol. Chem. 284: 27393-27401; 2009.
140. Sultana Butterfield, R. D.A. Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment. Neurochem. Res 32: 655-662; 2007.
141. Camins, A.; Verdaguer, E.; Folch, J.; Canudas, A. M.; Pallas, M. The role of CDK5/P25 formation/inhibition in neurodegeneration. Drug News Perspect. 19: 453-460; 2006. (Pubitemid 46050819)
142. Keeney, J.T.; Swomley, A.M.; Harris, J.L.; Fiorini, A.; Mitov, M.I.; Perluigi, M.; Sultana, R., Butterfield, D.A. Cell cycle proteins in brain in mild cognitive impairment: insights into progression to Alzheimer disease. Neurotox. Res. 2011.
143. Goshima, Y.; Nakamura, F.; Strittmatter, P.; Strittmatter, S. M. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 376: 509-514; 1995.
144. Yoshimura, T.; Kawano, Y.; Arimura, N.; Kawabata, S.; Kikuchi, A.; Kaibuchi, K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120: 137-149; 2005. (Pubitemid 40094609)
145. Williamson, R.; van Aalten, L.; Mann, D. M.; Platt, B.; Plattner, F.; Bedford, L.; Mayer, J.; Howlett, D.; Usardi, A.; Sutherland, C.; Cole, A. R. CRMP2 hyperphosphorylation is characteristic of Alzheimer's disease and not a feature common to other neurodegenerative diseases. J. Alzheimers Dis. 27: 615-625; 2011.
146. Cole, A. R.; Noble, W.; van Aalten, L.; Plattner, F.; Meimaridou, R.; Hogan, D.; Taylor, M.; LaFrancois, J.; Gunn-Moore, F.; Verkhratsky, A.; Oddo, S.; LaFerla, F.; Giese, K. P.; Dineley, K. T.; Duff, K.; Richardson, J. C.; Yan, S. D.; Hanger, D. P.; Allan, S. M.; Sutherland, C. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J. Neurochem. 103: 1132-1144; 2007. (Pubitemid 47568734)
147. Lu, P. J.; Wulf, G.; Zhou, X. Z.; Davies, P.; Lu, K. P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399: 784-788; 1999. (Pubitemid 29293174)
148. Zhang, Z.; Majava, V.; Greffier, A.; Hayes, R. L.; Kursula, P.; Wang, K. K. Collapsin response mediator protein-2 is a calmodulin-binding protein. Cell. Mol. Life Sci. 66: 526-536; 2009.
149. Al-Hallaq, R. A.; Conrads, T. P.; Veenstra, T. D.; Wenthold, R. J. NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J. Neurosci. 27: 8334-8343; 2007. (Pubitemid 47219608)
150. Wilson, S. M.; Brittain, J. M.; Piekarz, A. D.; Ballard, C. J.; Ripsch, M. S.; Cummins, T. R.; Hurley, J. H.; Khanna, M.; Hammes, N. M.; Samuels, B. C.; White, F. A.; Khanna, R. Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. Channels (Austin) 5: 449-456; 2011.
151. Hensley, K.; Venkova, K.; Christov, A.; Gunning, W.; Park, J. Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications. Mol. Neurobiol. 43: 180-191; 2011.
152. Kawano, Y.; Yoshimura, T.; Tsuboi, D.; Kawabata, S.; Kaneko-Kawano, T.; Shirataki, H.; Takenawa, T.; Kaibuchi, K. CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol. Cell. Biol. 25: 9920-9935; 2005. (Pubitemid 41572740)
153. Inagaki, N.; Chihara, K.; Arimura, N.; Menager, C.; Kawano, Y.; Matsuo, N.; Nishimura, T.; Amano, M.; Kaibuchi, K. CRMP-2 induces axons in cultured hippocampal neurons. Nat. Neurosci. 4: 781-782; 2001. (Pubitemid 32702507)
154. Reddy, P. H.; Beal, M. F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol. Med 14: 45-53; 2008.
155. Blass, J. P.; Gibson, G. E. Correlations of disability and biologic alterations in Alzheimer brain and test of significance by a therapeutic trial in humans. J. Alzheimers Dis 9: 207-218; 2006. (Pubitemid 44078646)
156. Fernandez-Vizarra, P.; Fernandez, A. P.; Castro-Blanco, S.; Serrano, J.; Bentura, M. L.; Martinez-Murillo, R.; Martinez, A.; Rodrigo, J. Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. Histol. Histopathol. 19: 823-844; 2004. (Pubitemid 38855065)
157. Calkins, M. J.; Manczak, M.; Mao, P.; Shirendeb, U.; Reddy, P. H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet 20: 4515-4529; 2011.
158. Lustbader, J. W.; Cirilli, M.; Lin, C.; Xu, H. W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L. F.; Walker, D. G.; Kuppusamy, P.; Zewier, Z. L.; Arancio, O.; Stern, D.; Yan, S. S.; Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304: 448-452; 2004. (Pubitemid 38495942)
159. Rhein, V.; Eckert, A. Effects of Alzheimer's amyloid-beta and tau protein on mitochondrial function - role of glucose metabolism and insulin signalling. Arch. Physiol. Biochem 113: 131-141; 2007. (Pubitemid 47547386)
160. Leuner, K.; Hauptmann, S.; Abdel-Kader, R.; Scherping, I.; Keil, U.; Strosz-najder, J. B.; Eckert, A.; Muller, W. E. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid. Redox Signal. 9: 1659-1675; 2007. (Pubitemid 47462969)
161. Sultana Butterfield, R. D.A. Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J. Bioenerg. Biomembr 41: 441-446; 2009.
162. Burwick, N. R.; Wahl, M. L.; Fang, J.; Zhong, Z.; Moser, T. L.; Li, B.; Capaldi, R. A.; Kenan, D. J.; Pizzo, S. V. An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface. J. Biol. Chem. 280: 1740-1745; 2005.
163. Chi, S. L.; Pizzo, S. V. Cell surface F1Fo ATP synthase: a new paradigm? Ann. Med. 38: 429-438; 2006. (Pubitemid 44484880)
164. Schagger, H.; Ohm, T. G. Human diseases with defects in oxidative phosphorylation. 2. F1F0 ATP-synthase defects in Alzheimer disease revealed by blue native polyacrylamide gel electrophoresis. Eur. J. Biochem 227: 916-921; 1995.
165. Lu, T.; Pan, Y.; Kao, S. Y.; Li, C.; Kohane, I.; Chan, J.; Yankner, B. A. Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891; 2004. (Pubitemid 38843301)
166. Terni, B.; Boada, J.; Portero-Otin, M.; Pamplona, R.; Ferrer, I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer's disease pathology. Brain Pathol 20: 222-233; 2010.
167. Busciglio, J.; Pelsman, A.; Wong, C.; Pigino, G.; Yuan, M.; Mori, H.; Yankner, B. A. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33: 677-688; 2002. (Pubitemid 34219240)
168. Sergeant, N.; Wattez, A.; Galvan-valencia, M.; Ghestem, A.; David, J. P.; Lemoine, J.; Sautiere, P. E.; Dachary, J.; Mazat, J. P.; Michalski, J. C.; Velours, J.; Mena-Lopez, R.; Delacourte, A. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience 117: 293-303; 2003. (Pubitemid 36259745)
169. Vacirca, D.; Barbati, C.; Scazzocchio, B.; Masella, R.; Rosano, G.; Malorni, W.; Ortona, E. Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level. J. Alzheimers Dis. 26: 441-445; 2011.
170. Vacirca, D.; Delunardo, F.; Matarrese, P.; Colasanti, T.; Margutti, P.; Siracu-sano, A.; Pontecorvo, S.; Capozzi, A.; Sorice, M.; Francia, A.; Malorni, W.; Ortona, E. Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer's disease. Neurobiol. Aging 33: 753-766; 2012.)